Literature DB >> 9616211

The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection.

D H Dockrell1, A D Badley, J S Villacian, C J Heppelmann, A Algeciras, S Ziesmer, H Yagita, D H Lynch, P C Roche, P J Leibson, C V Paya.   

Abstract

Fas/Fas Ligand (FasL) interactions play a significant role in peripheral T lymphocyte homeostasis and in certain pathological states characterized by T cell depletion. In this study, we demonstrate that antigen-presenting cells such as monocyte-derived human macrophages (MDM) but not monocyte-derived dendritic cells express basal levels of FasL. HIV infection of MDM increases FasL protein expression independent of posttranslational mechanisms, thus highlighting the virus-induced transcriptional upregulation of FasL. The in vitro relevance of these observations is confirmed in human lymphoid tissue. FasL protein expression is constitutive and restricted to tissue macrophages and not dendritic cells. Moreover, a significant increase in macrophage-associated FasL is observed in lymphoid tissue from HIV (+) individuals (P < 0.001), which is further supported by increased levels of FasL mRNA using in situ hybridization. The degree of FasL protein expression in vivo correlates with the degree of tissue apoptosis (r = 0.761, P < 0. 001), which is significantly increased in tissue from HIV-infected patients (P < 0.001). These results identify human tissue macrophages as a relevant source for FasL expression in vitro and in vivo and highlight the potential role of FasL expression in the immunopathogenesis of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9616211      PMCID: PMC508829          DOI: 10.1172/JCI1171

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

1.  CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.

Authors:  L J Zhou; T F Tedder
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

2.  Transcriptional regulation of the human FasL promoter-enhancer region.

Authors:  C J Holtz-Heppelmann; A Algeciras; A D Badley; C V Paya
Journal:  J Biol Chem       Date:  1998-02-20       Impact factor: 5.157

3.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

4.  Selective activation-induced apoptosis of peripheral T cells imposed by macrophages. A potential mechanism of antigen-specific peripheral lymphocyte deletion.

Authors:  D H Munn; J Pressey; A C Beall; R Hudes; M R Alderson
Journal:  J Immunol       Date:  1996-01-15       Impact factor: 5.422

5.  Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes.

Authors:  A D Badley; J A McElhinny; P J Leibson; D H Lynch; M R Alderson; C V Paya
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

6.  Apoptotic depletion of CD4+ T cells in idiopathic CD4+ T lymphocytopenia.

Authors:  J Laurence; D Mitra; M Steiner; D H Lynch; F P Siegal; L Staiano-Coico
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

7.  Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120.

Authors:  M O Westendorp; R Frank; C Ochsenbauer; K Stricker; J Dhein; H Walczak; K M Debatin; P H Krammer
Journal:  Nature       Date:  1995-06-08       Impact factor: 49.962

8.  Fas ligand in human serum.

Authors:  M Tanaka; T Suda; K Haze; N Nakamura; K Sato; F Kimura; K Motoyoshi; M Mizuki; S Tagawa; S Ohga; K Hatake; A H Drummond; S Nagata
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

9.  Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.

Authors:  P R Galle; W J Hofmann; H Walczak; H Schaller; G Otto; W Stremmel; P H Krammer; L Runkel
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

10.  Metalloproteinase-mediated release of human Fas ligand.

Authors:  N Kayagaki; A Kawasaki; T Ebata; H Ohmoto; S Ikeda; S Inoue; K Yoshino; K Okumura; H Yagita
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  26 in total

1.  Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge.

Authors:  S S Cohen; C Li; L Ding; Y Cao; A B Pardee; E M Shevach; D I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Thorsten Demberg; Ruth H Florese; Megan J Heath; Kay Larsen; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; David Venzon; Richard Grant; L Jean Patterson; Birgit Korioth-Schmitz; Adam Buzby; Dilani Dombagoda; David C Montefiori; Norman L Letvin; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

3.  Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation.

Authors:  Toshimitsu Suhara; Hyo-Soo Kim; Lorrie A Kirshenbaum; Kenneth Walsh
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

4.  In vivo analysis of Fas/FasL interactions in HIV-infected patients.

Authors:  A D Badley; D H Dockrell; A Algeciras; S Ziesmer; A Landay; M M Lederman; E Connick; H Kessler; D Kuritzkes; D H Lynch; P Roche; H Yagita; C V Paya
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

Review 5.  Nelfinavir: an update on its use in HIV infection.

Authors:  A Bardsley-Elliot; G L Plosker
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

6.  Up-regulation of Fas ligand (FasL) in the central nervous system: a mechanism of immune evasion by rabies virus.

Authors:  Leïla Baloul; Serge Camelo; Monique Lafon
Journal:  J Neurovirol       Date:  2004-12       Impact factor: 2.643

7.  Herpes simplex virus type 1-induced FasL expression in human monocytic cells and its implications for cell death, viral replication, and immune evasion.

Authors:  Alexandre Iannello; Olfa Debbeche; Raoudha El Arabi; Suzanne Samarani; David Hamel; Flore Rozenberg; Nikolaus Heveker; Ali Ahmad
Journal:  Viral Immunol       Date:  2011-02       Impact factor: 2.257

8.  Isolation of a TRAIL antagonist from the serum of HIV-infected patients.

Authors:  David J Schnepple; Brett Shepard; Gary D Bren; Nathan W Cummins; Sekar Natesampillai; Sergey Trushin; Alicia Algeciras-Schimnich; Xue W Meng; Amy M Sainski; Stacey A Rizza; Scott H Kaufmann; Andrew D Badley
Journal:  J Biol Chem       Date:  2011-08-22       Impact factor: 5.157

9.  Increased Fas-mediated apoptosis in polymorphonuclear cells from HIV-infected patients.

Authors:  S Salmen; G Terán; L Borges; L Goncalves; B Albarrán; H Urdaneta; H Montes; L Berrueta
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

10.  CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling.

Authors:  Gudrun Strauss; Jonathan A Lindquist; Nathalie Arhel; Edward Felder; Sabine Karl; Tobias L Haas; Simone Fulda; Henning Walczak; Frank Kirchhoff; Klaus-Michael Debatin
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.